Please assess the completion status of the following clinical trial:

Trial Title: A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have documentation of histologically or cytologically confirmed metastatic or locally advanced adenocarcinoma of the distal esophagus, GE junction or stomach~* Patients must have documentation of histologically or cytologically confirmed HER2 expression~* Patients must be ≥18 years of age~* Patients must have ECOG PS of 0, 1, or 2~* Patients must have adequate hematologic status, renal and hepatic function~Exclusion Criteria:~* Patients with known hypersensitivity to any of the components of MM-111~* Patients with a known history of hypersensitivity to paclitaxel or other drugs formulated in Cremophor® EL~* Patients with a known history of hypersensitivity to trastuzumab or any of its components (group 1 patients only)~* Patients with an active infection or with an unexplained fever \>38.5°C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1a (Type: EXPERIMENTAL): MM-111 + Paclitaxel + Trastuzumab
- Arm 1b (Type: ACTIVE_COMPARATOR): Paclitaxel + Trastuzumab

Based on this trial design, predict the completion outcome and termination type (if applicable).